Recommendation of Polish clinical experts on the strategy of treatment with cladribine tablets depending on the patient’s characteristic Experts recommendations
Article Sidebar
Main Article Content
Abstract
The therapy with cladribine in tablets in a standard regimen, available in the multiple sclerosis therapeutic program, stabilizes the course of the disease in a significant percentage of patients. At the same time, both results of clinical trials, data from current clinical practice and the own experience of many neurologists indicate that disease activity after administration of 2 cycles of cladribine tablets may occur in some patients, both within 2 years of active treatment and later, i.e. in year 3 and 4 and after 4 years. Therefore, some patients may experience clinical and/or radiological activity both after the lapse of the registered 4-year treatment period with 2-year active treatment and even before its expiration. In present article, a group of Polish experts referred to known and described in the literature types of response to cladribine in tablets and formulated recommendations regarding the management in situations of incomplete treatment effectiveness or recurrence of the disease despite its use in the total recommended and registered dose.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician’s Review. Neurol Ther. 2022; 11: 571-95.
3. Charakterystyka produktu leczniczego Mavenclad 03.2022.
4. Updated MS Guidelines Advocate Earlier, More Aggressive Treatment. (access: 31.03.2023).
5. Herman R, Karlsson MO, Novakovic AM et al. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. Clin Pharmacokinet. 2019; 58: 283-97.
6. Giovannoni G, Leist T, Aydemir A et al on behalf of the CLASSIC-MS Steering Committee. Long-term efficacy for patients receiving cladribine tablets in CLARITY/ CLARITY Extension: primary results from 9–15 years of follow-up in the CLASSIC-MS Study. ECTRIMS 13–15 October 2021.
7. Meuth SG, Bayas A, Kallmann B et al. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother. 2020; 21: 1965-9.
8. Meuth SG, Bayas A, Kallmann B et al. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4 2022. Expert Opin Pharmacother. 2022; 23(13): 1503-10. http://doi.org/10.1080/14656566.2022.2106783.
9. Giovannoni G, Comi G, Cook S et al. A placebo controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med NEJM. 2010; 362: 416-26.
10. Giovannoni G, Sorensen PS, Cook S et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018; 24: 1594-604.
11. Petracca M, Ruggieri S, Barbuti E et al. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study. Neurol Ther. 2022; 11(3): 1193-208. http://doi.org/10.1007/s40120-022-00364-6.
12. Rauma I, Viitala M, Kuusisto H et al. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022; 61: 103755.
13. Annovazzi P, Frau J, Margoni M et al. Two year relapse-free and NEDA status for Cladribine in a real life population: a multicentre study ECTRIMS 2021 [P842].
14. Giovannoni G, Sorensen PS, Cook S et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler. 2019; 25(6): 819-27.
1. Habek M, Drulovic J, Brecl Jacob G et al. Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Neurol Ther. 2023; 12(1): 25-37. http://doi.org/10.1007/s40120-022-00422-z.
2. Oreja-Guevara C, Brownlee W, Celius EG et al. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence. Mult Scler Relat Disord. 2023; 69: 104459. http://doi.org/10.1016/j.msard.2022.104459.
3. Meca-Lallana V, García Domínguez JM, López Ruiz R et al. Expert-Agreed Practical Recommendations on the Use of Cladribine. Neurol Ther. 2022; 11: 1475-88. http://doi.org/10.1007/s40120-022-00394-0.